- Home
- IINN vs ATOS Comparison
IINN vs ATOS Comparison
Compare IINN & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IINN | ATOS |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3M | 36.2M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | IINN | ATOS |
|---|---|---|
| Price | $0.39 | $5.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 330.6K | 52.6K |
| Earning Date | 03-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | $16,841.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.53 |
| 52 Week High | $1.65 | $7.56 |
Technical Indicators
Market Signals| Indicator | IINN | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 44.30 |
| Support Level | $0.34 | $4.59 |
| Resistance Level | $0.63 | $6.18 |
| Average True Range (ATR) | 0.04 | 0.37 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 4.93 | 15.11 |
Price Performance
Historical ComparisonAbout IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.